Requests that the FDA require the immediate revision of all SSRI and SNRI antidepressant product labels (included branded and generic formulations) to warn of serious and severe risks
🏛 Food and Drug Administration (FDA)FDA-2025-P-1305
Documents
1
Total comments
0
all analyzed
Comment status
Closed
Last activity
—
In this docket
Documents
Rules, notices, and supporting material — the primary rule pinned first.
No documents mirrored for this docket yet.